{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:10:28Z","timestamp":1760739028788,"version":"build-2065373602"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"DOI":"10.7759\/cureus.94818","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:35:10Z","timestamp":1760736910000},"source":"Crossref","is-referenced-by-count":0,"title":["Statin Use and the Risk of Developing Graves\u2019 Orbitopathy in Patients With Graves\u2019 Disease: A Systematic Review and Meta-Analysis With Regional and Gender-Stratified Analyses"],"prefix":"10.7759","author":[{"given":"Marjeta","family":"Kermaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bezalel","family":"Hakkeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Fero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay Kumar","family":"Doddapaneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agron","family":"Ylli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn RS","year":"2010","unstructured":"Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010, 362:726-38. 10.1056\/NEJMra0905750","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.09.004","article-title":"Prevention of Graves' ophthalmopathy","volume":"26","author":"Bartalena L","year":"2012","unstructured":"Bartalena L. Prevention of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012, 26:371-9. 10.1016\/j.beem.2011.09.004","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' Disease","volume":"375","author":"Smith TJ","year":"2016","unstructured":"Smith TJ, Heged\u00fcs L. Graves' Disease. N Engl J Med. 2016, 375:1552-65. 10.1056\/NEJMra1510030","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain MK","year":"2005","unstructured":"Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005, 4:977-87. 10.1038\/nrd1901","journal-title":"Nat Rev Drug Discov"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon J","year":"2004","unstructured":"Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004, 109:III39-43. 10.1161\/01.CIR.0000131517.20177.5a","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0323749","article-title":"Impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases: a systematic review and meta-analysis","volume":"20","author":"Sabeel S","year":"2025","unstructured":"Sabeel S, Motaung B, Nguyen KA, et al.. Impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases: a systematic review and meta-analysis. PLoS One. 2025, 20:e0323749. 10.1371\/journal.pone.0323749","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-025-09653-2","article-title":"Statins and adhesion molecules: a review of a novel pleiotropic property of statins","volume":"73","author":"Sadeghi M","year":"2025","unstructured":"Sadeghi M, Dehnavi S, Shahbaz SK, Koushki K, Butler AE, Jamialahmadi T, Sahebkar A. Statins and adhesion molecules: a review of a novel pleiotropic property of statins. Immunol Res. 2025, 73:97. 10.1007\/s12026-025-09653-2","journal-title":"Immunol Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2020.105735","article-title":"Statins reduce vascular inflammation in atherogenesis: a review of underlying molecular mechanisms","volume":"122","author":"Liberale L","year":"2020","unstructured":"Liberale L, Carbone F, Montecucco F, Sahebkar A. Statins reduce vascular inflammation in atherogenesis: a review of underlying molecular mechanisms. Int J Biochem Cell Biol. 2020, 122:105735. 10.1016\/j.biocel.2020.105735","journal-title":"Int J Biochem Cell Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.5103","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease","volume":"133","author":"Stein JD","year":"2015","unstructured":"Stein JD, Childers D, Gupta S, et al.. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol. 2015, 133:290-6. 10.1001\/jamaophthalmol.2014.5103","journal-title":"JAMA Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab070","article-title":"Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves disease","volume":"106","author":"Nilsson A","year":"2021","unstructured":"Nilsson A, Tsoumani K, Planck T. Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves disease. J Clin Endocrinol Metab. 2021, 106:1325-32. 10.1210\/clinem\/dgab070","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02513-z","article-title":"Sex-specific risk factors associated with graves' orbitopathy in Korean patients with newly diagnosed Graves' disease","volume":"37","author":"Lee J","year":"2023","unstructured":"Lee J, Kang J, Ahn HY, Lee JK. Sex-specific risk factors associated with graves' orbitopathy in Korean patients with newly diagnosed Graves' disease. Eye (Lond). 2023, 37:3382-91. 10.1038\/s41433-023-02513-z","journal-title":"Eye (Lond)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0536","article-title":"Statin use and the risk of Graves\u2019 orbitopathy: a nationwide population-based cohort study","volume":"35","author":"Chou YT","year":"2025","unstructured":"Chou YT, Lai CC, Li CY, et al.. Statin use and the risk of Graves\u2019 orbitopathy: a nationwide population-based cohort study. Thyroid. 2025, 35:199-207. 10.1089\/thy.2024.0536","journal-title":"Thyroid"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-024-00930-1","article-title":"An appraisal of the preventive effect of statins on the development of Graves\u2019 ophthalmopathy: a hospital-based cohort study","volume":"13","author":"Hsu GC","year":"2024","unstructured":"Hsu GC, Shih SR, Chang FY, Liao SL, Wei YH. An appraisal of the preventive effect of statins on the development of Graves\u2019 ophthalmopathy: a hospital-based cohort study. Ophthalmol Ther. 2024, 13:1499-511. 10.1007\/s40123-024-00930-1","journal-title":"Ophthalmol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2813","article-title":"Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease","volume":"91","author":"Eckstein AK","year":"2006","unstructured":"Eckstein AK, Plicht M, Lax H, et al.. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006, 91:3464-70. 10.1210\/jc.2005-2813","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346614","article-title":"Pathogenesis of Graves' orbitopathy: a 2010 update","volume":"33","author":"Smith TJ","year":"2010","unstructured":"Smith TJ. Pathogenesis of Graves' orbitopathy: a 2010 update. J Endocrinol Invest. 2010, 33:414-21. 10.1007\/BF03346614","journal-title":"J Endocrinol Invest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nri3520","article-title":"Macrophages in atherosclerosis: a dynamic balance","volume":"13","author":"Moore KJ","year":"2013","unstructured":"Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013, 13:709-21. 10.1038\/nri3520","journal-title":"Nat Rev Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(02)03268-x","article-title":"Effects of statins on inflammation in patients with acute and chronic coronary syndromes","volume":"91","author":"Kinlay S","year":"2003","unstructured":"Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol. 2003, 91:9B-13B. 10.1016\/s0002-9149(02)03268-x","journal-title":"Am J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00229","article-title":"Gender differences at the onset of autoimmune thyroid diseases in children and adolescents","volume":"11","author":"Calcaterra V","year":"2020","unstructured":"Calcaterra V, Nappi RE, Regalbuto C, et al.. Gender differences at the onset of autoimmune thyroid diseases in children and adolescents. Front Endocrinol (Lausanne). 2020, 11:229. 10.3389\/fendo.2020.00229","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0030","article-title":"Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function","volume":"24","author":"Tomer Y","year":"2003","unstructured":"Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev. 2003, 24:694-717. 10.1210\/er.2002-0030","journal-title":"Endocr Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00450.x","article-title":"A population-based study of Graves' disease in Danish twins","volume":"48","author":"Brix TH","year":"1998","unstructured":"Brix TH, Christensen K, Holm NV, Harvald B, Heged\u00fcs L. A population-based study of Graves' disease in Danish twins. Clin Endocrinol (Oxf). 1998, 48:397-400. 10.1046\/j.1365-2265.1998.00450.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref22","unstructured":"Risk Of Bias In Non-Randomized Studies - of Interventions (ROBINS-I). (2025). Accessed. 2025: https:\/\/methods.cochrane.org\/bias\/risk-bias-non-randomized-studies-interventions."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo D","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018, 27:1785-805. 10.1177\/0962280216669183","journal-title":"Stat Methods Med Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan X","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014, 14:135. 10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"ref25","unstructured":"Review Manager (RevMan). (2020). Accessed. 2025: https:\/\/test-training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/review-manager-revman\/download-revm...."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.84388","article-title":"Preventing thyroid eye disease with statins: evidence from a meta-analysis","volume":"17","author":"Barnett MJ","year":"2025","unstructured":"Barnett MJ, John TA, Casipit C, Eidbo S, Lam J, Anastasopoulou C. Preventing thyroid eye disease with statins: evidence from a meta-analysis. Cureus. 2025, 17:e84388. 10.7759\/cureus.84388","journal-title":"Cureus"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31643-3","article-title":"Statin protects men but not women with HIV against loss of muscle mass, strength, and physical function: a pilot study","volume":"13","author":"C\u00e1rdenas JD","year":"2023","unstructured":"C\u00e1rdenas JD, Oliveira VH, Borsari AL, Marinello PC, Longenecker CT, Deminice R. Statin protects men but not women with HIV against loss of muscle mass, strength, and physical function: a pilot study. Sci Rep. 2023, 13:4693. 10.1038\/s41598-023-31643-3","journal-title":"Sci Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02981-x","article-title":"Investigating genetically mimicked effects of statins via HMGCR inhibition on immune-related diseases in men and women using Mendelian randomization","volume":"11","author":"Yang G","year":"2021","unstructured":"Yang G, Schooling CM. Investigating genetically mimicked effects of statins via HMGCR inhibition on immune-related diseases in men and women using Mendelian randomization. Sci Rep. 2021, 11:23416. 10.1038\/s41598-021-02981-x","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.032","article-title":"Sex differences in high-intensity statin use following myocardial infarction in the United States","volume":"71","author":"Peters SA","year":"2018","unstructured":"Peters SA, Colantonio LD, Zhao H, et al.. Sex differences in high-intensity statin use following myocardial infarction in the United States. J Am Coll Cardiol. 2018, 71:1729-37. 10.1016\/j.jacc.2018.02.032","journal-title":"J Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.1047","article-title":"Assessment of sex disparities in nonacceptance of statin therapy and low-density lipoprotein cholesterol levels among patients at high cardiovascular risk","volume":"6","author":"Brown CJ","year":"2023","unstructured":"Brown CJ, Chang LS, Hosomura N, et al.. Assessment of sex disparities in nonacceptance of statin therapy and low-density lipoprotein cholesterol levels among patients at high cardiovascular risk. JAMA Netw Open. 2023, 6:e231047. 10.1001\/jamanetworkopen.2023.1047","journal-title":"JAMA Netw Open"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1089\/105072501300176417","article-title":"Environmental iodine intake affects the type of nonmalignant thyroid disease","volume":"11","author":"Laurberg P","year":"2001","unstructured":"Laurberg P, B\u00fclow Pedersen I, Knudsen N, Ovesen L, Andersen S. Environmental iodine intake affects the type of nonmalignant thyroid disease. Thyroid. 2001, 11:457-69. 10.1089\/105072501300176417","journal-title":"Thyroid"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla G","year":"2021","unstructured":"Lanzolla G, Sabini E, Leo M, et al.. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol. 2021, 9:733-42. 10.1016\/S2213-8587(21)00238-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae877","article-title":"Comprehensive comparisons of different treatments for active Graves orbitopathy: a systematic review and Bayesian model-based network meta-analysis","volume":"110","author":"Xu Y","year":"2025","unstructured":"Xu Y, Liu R, Huang L, Qin Y, Liu W, Huang S, Zhang J. Comprehensive comparisons of different treatments for active Graves orbitopathy: a systematic review and Bayesian model-based network meta-analysis. J Clin Endocrinol Metab. 2025, 110:1792-801. 10.1210\/clinem\/dgae877","journal-title":"J Clin Endocrinol Metab"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03680-5","article-title":"Statins and thyroid eye disease (TED): a systematic review","volume":"85","author":"Malboosbaf R","year":"2024","unstructured":"Malboosbaf R, Maghsoomi Z, Emami Z, Khamseh ME, Azizi F. Statins and thyroid eye disease (TED): a systematic review. Endocrine. 2024, 85:11-7. 10.1007\/s12020-023-03680-5","journal-title":"Endocrine"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311724","article-title":"Financial resources, access to care, and quality of care mediate racial disparities in statin usage for secondary prevention","volume":"19","author":"Wong C","year":"2024","unstructured":"Wong C, Marrast L, Rasul R, et al.. Financial resources, access to care, and quality of care mediate racial disparities in statin usage for secondary prevention. PLoS One. 2024, 19:e0311724. 10.1371\/journal.pone.0311724","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.0228","article-title":"Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020","volume":"8","author":"Jacobs JA","year":"2023","unstructured":"Jacobs JA, Addo DK, Zheutlin AR, et al.. Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol. 2023, 8:443-52. 10.1001\/jamacardio.2023.0228","journal-title":"JAMA Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2015.09.013","article-title":"Dyslipidemia in special ethnic populations","volume":"45","author":"Pu J","year":"2016","unstructured":"Pu J, Romanelli R, Zhao B, et al.. Dyslipidemia in special ethnic populations. Endocrinol Metab Clin North Am. 2016, 45:205-16. 10.1016\/j.ecl.2015.09.013","journal-title":"Endocrinol Metab Clin North Am"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/419383-statin-use-and-the-risk-of-developing-graves-orbitopathy-in-patients-with-graves-disease-a-systematic-review-and-meta-analysis-with-regional-and-gender-stratified-analyses","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:35:16Z","timestamp":1760736916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/419383-statin-use-and-the-risk-of-developing-graves-orbitopathy-in-patients-with-graves-disease-a-systematic-review-and-meta-analysis-with-regional-and-gender-stratified-analyses"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.94818","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}